MX2015012905A - Formulaciones de factor viii recombinantes. - Google Patents

Formulaciones de factor viii recombinantes.

Info

Publication number
MX2015012905A
MX2015012905A MX2015012905A MX2015012905A MX2015012905A MX 2015012905 A MX2015012905 A MX 2015012905A MX 2015012905 A MX2015012905 A MX 2015012905A MX 2015012905 A MX2015012905 A MX 2015012905A MX 2015012905 A MX2015012905 A MX 2015012905A
Authority
MX
Mexico
Prior art keywords
factor viii
recombinant factor
viii formulations
formulations
polymer
Prior art date
Application number
MX2015012905A
Other languages
English (en)
Spanish (es)
Inventor
De Qian Wang
Xinghang Ma
Nelly Tsvetkova
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2015012905A publication Critical patent/MX2015012905A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015012905A 2013-03-15 2014-03-11 Formulaciones de factor viii recombinantes. MX2015012905A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799495P 2013-03-15 2013-03-15
US201361869191P 2013-08-23 2013-08-23
PCT/US2014/023357 WO2014150477A1 (en) 2013-03-15 2014-03-11 Recombinant factor viii formulations

Publications (1)

Publication Number Publication Date
MX2015012905A true MX2015012905A (es) 2016-06-16

Family

ID=51580768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012905A MX2015012905A (es) 2013-03-15 2014-03-11 Formulaciones de factor viii recombinantes.

Country Status (17)

Country Link
US (1) US20160030524A1 (enExample)
EP (1) EP2970430A4 (enExample)
JP (1) JP2016518321A (enExample)
KR (1) KR20150132449A (enExample)
CN (1) CN105209487A (enExample)
AU (1) AU2014237111B2 (enExample)
BR (1) BR112015022730A2 (enExample)
CA (1) CA2905739A1 (enExample)
HK (1) HK1213273A1 (enExample)
MX (1) MX2015012905A (enExample)
PE (1) PE20160121A1 (enExample)
RU (1) RU2015144076A (enExample)
SG (2) SG10201803999UA (enExample)
TW (1) TW201521761A (enExample)
UY (1) UY35412A (enExample)
WO (1) WO2014150477A1 (enExample)
ZA (1) ZA201507684B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3247400A1 (en) * 2015-01-18 2017-11-29 Biogen MA Inc. Formulations and screening of biological therapeutic agents
CN116949052A (zh) 2015-11-13 2023-10-27 武田药品工业株式会社 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体
KR20210034013A (ko) 2018-07-16 2021-03-29 박스알타 인코퍼레이티드 발현이 증가된 재조합 fviii 변이체들을 인코딩하는 바이러스 벡터를 이용한 혈우병의 유전적 치료법
TWI851647B (zh) 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US20220305089A1 (en) * 2019-08-16 2022-09-29 Octapharma Ag Stabilizing buffer for factor viii and vwf

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
EP1152450A4 (en) * 1999-02-01 2004-04-14 Nippon Electric Glass Co CATHODE RAY TUBE AND METHOD FOR THE PRODUCTION THEREOF
ES2435141T3 (es) * 1999-02-22 2013-12-18 University Of Connecticut Nuevas formulaciones de factor VIII libres de albúmina
EP2110385A1 (en) * 2001-06-14 2009-10-21 The Scripps Research Institute Stabilized factor VIII with engineered disulfide bonds
GB0207092D0 (en) * 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
SI1824988T1 (sl) * 2004-11-12 2017-11-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
NZ572050A (en) * 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
US20100168018A1 (en) * 2008-11-07 2010-07-01 Baxter International Inc. Factor viii formulations
US20120121613A1 (en) * 2009-01-19 2012-05-17 Bayer Healthcare Llc Protein conjugate having an endopeptidase- cleavable bioprotective moiety

Also Published As

Publication number Publication date
WO2014150477A1 (en) 2014-09-25
RU2015144076A (ru) 2017-04-24
KR20150132449A (ko) 2015-11-25
ZA201507684B (en) 2017-06-28
UY35412A (es) 2014-10-31
SG10201803999UA (en) 2018-06-28
JP2016518321A (ja) 2016-06-23
AU2014237111B2 (en) 2018-06-21
CA2905739A1 (en) 2014-09-25
AU2014237111A1 (en) 2015-10-08
EP2970430A4 (en) 2017-01-11
SG11201507618YA (en) 2015-10-29
PE20160121A1 (es) 2016-03-03
BR112015022730A2 (pt) 2017-10-31
US20160030524A1 (en) 2016-02-04
EP2970430A1 (en) 2016-01-20
HK1213273A1 (zh) 2016-06-30
CN105209487A (zh) 2015-12-30
TW201521761A (zh) 2015-06-16

Similar Documents

Publication Publication Date Title
ZA202101142B (en) Methods and compositions comprising purified recombinant polypeptides
PH12016500316A1 (en) Improved adenovirus formulations
MX2016007063A (es) Peptidos terapeuticos.
MX2013015168A (es) Co-agonista del receptor de glucagon/glp-1.
PH12013502671A1 (en) Glucagon/glp-1 receptor co-agonists
HUE043537T2 (hu) Rekombináns VIII faktor fehérjék
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
SG11201505924TA (en) Factor viii polypeptide formulations
EP3033098A4 (en) Recombinant factor viii proteins
TR201905787T4 (tr) Liyofilize TAT-NR2B9C formülasyonu.
WO2013123046A3 (en) Cathode buffer materials and related devices and methods
HUE050362T2 (hu) Javított rekombináns fehérje expresszió hibrid CHEF1 promótert alkalmazva
MX2015012905A (es) Formulaciones de factor viii recombinantes.
EP3052526A4 (en) Recombinant polypeptides comprising mhc class ii 1 domains
MX349487B (es) Composiciones de higiene bucal.
AR095431A1 (es) Formulaciones de fviii recombinante
UA90689U (uk) Комплексний протипаразитарний препарат "лактоверм"
ES2426017A2 (es) Microemulsión que comprende colagenasa y usos
JO3497B1 (ar) مستحضر صيدلي يشتمل على hcg مأشوب
GB201210286D0 (en) Recombinant polypeptide
TH1101001042B (th) รีคอมบิเเนนท์เวคเตอร์ซึ่งประกอบด้วยยีนที่เข้ารหัสฮิวเเมน กลูโคไคเนส